Transcriptomic analysis of chronic hepatitis b and c and liver cancer reveals microrna-mediated control of cholesterol synthesis programs

mBio

Volumn 6, Issue 6, 2015, Pages

  Selitsky, Sara R ^a,b   Dinh, Timothy A ^a,b   Toth, Cynthia L ^c   Kurtz, C Lisa ^b   Honda, Masao ^d   Struck, Benjamin R ^e   Kaneko, Shuichi ^d   Vickers, Kasey C ^c   Lemon, Stanley M ^a,b   Sethupathy, Praveen ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^e Financial Tailor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; MICRORNA; MICRORNA 1307; MICRORNA 21; MICRORNA 224; MICRORNA 27; MICRORNA 33; UNCLASSIFIED DRUG; CHOLESTEROL; GENETIC MARKER;

ADULT; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TRANSCRIPTOMICS; VIRUS CARCINOGENESIS; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; LIVER; LIVER TUMOR; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; CHOLESTEROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER; LIVER NEOPLASMS; MICRORNAS;

EID: 84952803164     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01500-15     Document Type: Article

References (59)

1. Arzumanyan A, Reis HMGPV, Feitelson MA. 2013. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13:123-135. http://dx.doi.org/10.1038/nrc3449.
2. Su TC, Lee YT, Cheng TJ, Chien HP, Wang JD. 2004. Chronic hepatitis B virus infection and dyslipidemia. J Formos Med Assoc 103:286-291.
3. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. 2009. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50:1030-1037. http:// dx.doi.org/10.1002/hep.23219.
4. Chen Z, Keech A, Collins R, Slavin B, Chen J, Campbell TC, Peto R. 1993. Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer. BMJ 306:890-894. http://dx.doi.org/10.1136/bmj.306.6882.890.
5. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. 2013. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses 5:1292-1324. http:// dx.doi.org/10.3390/v5051292.
6. Jiang J, Nilsson-Ehle P, Xu N. 2006. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4. http://dx.doi.org/10.1186/ 1476-511X-5-4.
7. Jiang JT, Xu N, Zhang XY, Wu CP. 2007. Lipids changes in liver cancer. J Zhejiang Univ Sci B 8:398-409. http://dx.doi.org/10.1631/ jzus.2007.B0398.
8. Schaefer EA, Chung RT. 2013. HCV and host lipids: an intimate connection. Semin Liver Dis 33:358-368. http://dx.doi.org/10.1055/s-0033-1358524.
9. Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. 2011. MicroRNAs in lipid metabolism. Curr Opin Lipidol 22:86-92. http://dx.doi.org/ 10.1097/MOL.0b013e3283428d9d.
10. Flowers E, Froelicher ES, Aouizerat BE. 2013. MicroRNA regulation of lipid metabolism. Metab Clin Exp 62:12-20. http://dx.doi.org/10.1016/ j.metabol.2012.04.009.
11. Vickers KC, Sethupathy P, Baran-Gale J, Remaley AT. 2013. Complexity of microRNA function and the role of isomiRs in lipid homeostasis. J Lipids Res 54:1182-1191. http://dx.doi.org/10.1194/jlr.R034801.
12. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87-98. http://dx.doi.org/10.1016/j.cmet.2006.01.005.
13. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-1581. http://dx.doi.org/10.1126/science.1113329.
14. Choi SE, Fu T, Seok S, Kim DH, Yu E, Lee KW, Kang Y, Li X, Kemper B, Kemper JK. 2013. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 12: 1062-1072. http://dx.doi.org/10.1111/acel.12135.
15. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C. 2010. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570-1573. http://dx.doi.org/10.1126/science.1189862.
16. Marquart TJ, Allen RM, Ory DS, Baldan A. 2010. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 107:12228-12232. http://dx.doi.org/10.1073/pnas.1005191107.
17. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. 2010. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328:1566-1569. http:// dx.doi.org/10.1126/science.1189123.
18. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. 2013. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 19:892-900. http://dx.doi.org/10.1038/nm.3200.
19. Kurtz CL, Peck BCE, Fannin EE, Beysen C, Miao J, Landstreet SR, Ding S, Turaga V, Lund PK, Turner S, Biddinger SB, Vickers KC, Sethupathy P. 2014. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 63:3141-3148. http://dx.doi.org/ 10.2337/db13-1015.
20. Selitsky SR, Baran-Gale J, Honda M, Yamane D, Masaki T, Fannin EE, Guerra B, Shirasaki T, Shimakami T, Kaneko S, Lanford RE, Lemon SM, Sethupathy P. 2015. Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep 5:7675. http://dx.doi.org/10.1038/srep07675.
21. Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, Lanford RE, Lemon SM. 2013. MicroRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One 8:e76867. http:// dx.doi.org/10.1371/journal.pone.0076867.
22. Wang Z, Gerstein M, SnyderM. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57-63. http://dx.doi.org/10.1038/ nrg2484.
23. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A 86:1333-1337.
24. Le Page C, Genin P, Baines MG, Hiscott J. 2000. Interferon activation and innate immunity. Rev Immunogenet 2:374-386.
25. Zhao C, Dahlman-Wright K. 2010. Liver X receptor in cholesterol metabolism. J Endocrinol 204:233-240. http://dx.doi.org/10.1677/JOE-09-0271.
26. Edwards PA, Kennedy MA, Mak PA. 2002. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vasc Pharmacol 38:249-256. http://dx.doi.org/10.1016/S1537-1891(02)00175-1.
27. Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A. 2006. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 26:2731-2737. http:// dx.doi.org/10.1161/01.ATV.0000248101.93488.84.
28. Tanos R, Patel RD, Murray IA, Smith PB, Patterson AD, Perdew GH. 2012. Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent manner. Hepatology 55:1994-2004. http://dx.doi.org/10.1002/hep.25571.
29. Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. 2013. Beta cell 5=-shifted isomiRs are candidate regulatory hubs in type 2 diabetes. PLoS One 8:e73240. http://dx.doi.org/10.1371/journal.pone.0073240.
30. Chen Y, Chen J, Wang H, Shi J, Wu K, Liu S, Liu Y, Wu J. 2013. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 9:e1003248. http://dx.doi.org/ 10.1371/journal.ppat.1003248.
31. Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Tyrrell DL, Pezacki JP. 2014. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology 59:98-108. http:// dx.doi.org/10.1002/hep.26634.
32. Li GY, Zhou Y, Ying RS, Shi L, Cheng YQ, Ren JP, Griffin JWD, Jia ZS, Li CF, Moorman JP, Yao ZQ. 2015. Hepatitis C virus-induced reduction in miR-181a impairs CD4 T-cell responses through overexpression of DUSP6. Hepatology 61:1163-1173. http://dx.doi.org/10.1002/hep.27634.
33. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. 2010. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 88:169-1 7 5. http://dx.doi. org/1 0. 1 0 1 6 / j.antiviral.2010.08.008.
34. Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, Zhu Z, Jiao H, Lin J, Jiang K, Ding L, Zhang H, Cheng L, Fu H, Song Y, Jiang Y, Liu J, Wang R, Du N, Ye Q. 2013. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 123:630-645. http://dx.doi.org/ 10.1172/JCI64265.
35. Coppola N, Potenza N, Pisaturo M, Mosca N, Tonziello G, Signoriello G, Messina V, Sagnelli C, Russo A, Sagnelli E. 2013. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One 8:e65336. http://dx.doi.org/ 10.1371/journal.pone.0065336.
36. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. 2010. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107:264-269. http://dx.doi.org/10.1073/pnas.0907904107.
37. Sheng Y, Ding S, Chen K, Chen J, Wang S, Zou C, Zhang J, Cao Y, Huang A, Tang H. 2014. Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis. Biochem Cell Biol 92:152-162. http://dx.doi.org/10.1139/bcb-2013-0128.
38. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. 2014. Autophagy suppresses tumorigenesis of hepatitis B virusassociated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 59:505-517. http://dx.doi.org/10.1002/hep.26659.
39. Lendvai G, Jarmay K, Karacsony G, Halasz T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A. 2014. Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J Gastroenterol 20: 15343-15350. http://dx.doi.org/10.3748/wjg.v20.i41.15343.
40. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. 2011. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19:232-243. http:// dx.doi.org/10.1016/j.ccr.2011.01.001.
41. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, Collins FS, Remaley AT, Sethupathy P. 2013. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 57:533-542. http://dx.doi.org/10.1002/hep.25846.
42. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S, Yi M, Lemon SM, Kaneko S. 2013. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis Cvirus replication in human hepatoma cells. J Virol 87:5270-5286. http:// dx.doi.org/10.1128/JVI.03022-12.
43. Tsang J, Zhu J, van Oudenaarden A. 2007. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 26:753-767. http://dx.doi.org/10.1016/j.molcel.2007.05.018.
44. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, Fukami T, Yokoi T. 2011. PPARalpha is regulated by miR-21 and miR-27b in human liver. Pharm Res 28:2467-2476. http://dx.doi.org/10.1007/s11095-011-0473-y.
45. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. 2009. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 583:759-766. http:// dx.doi.org/10.1016/j.febslet.2009.01.034.
46. van der Meer DLM, Degenhardt T, Vaisanen S, de Groot PJ, Heinaniemi M, de Vries SC, Muller M, Carlberg C, Kersten S. 2010. Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIPchip analysis. Nucleic Acids Res 38:2839-2850. http://dx.doi.org/10.1093/ nar/gkq012.
47. Fernandez-Alvarez A, Alvarez MS, Gonzalez R, Cucarella C, Muntane J, CasadoM. 2011. Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 286:21466-21477. http://dx.doi.org/10.1074/jbc.M110.209973.
48. Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460:479-486. http://dx.doi.org/10.1038/nature08170.
49. Fernández-Hernando C. 2013. Emerging role of microRNAs in the regulation of lipid metabolism. Hepatology 57:432-434. http://dx.doi.org/ 10.1002/hep.25960.
50. Zhang M, Wu JF, Chen WJ, Tang SL, Mo ZC, Tang YY, Li Y, Wang JL, Liu XY, Peng J, Chen K, He PP, Lv YC, Ouyang XP, Yao F, Tang DP, Cayabyab FS, Zhang DW, Zheng XL, Tian GP, Tang CK. 2014. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis 234: 54-64. http://dx.doi.org/10.1016/j.atherosclerosis.2014.02.008.
51. Sun C, Huang F, Liu X, Xiao X, Yang M, Hu G, Liu H, Liao L. 2015. miR-21 regulates triglyceride and cholesterol metabolism in nonalcoholic fatty liver disease by targeting HMGCR. Int J Mol Med 35: 847-853. http://dx.doi.org/10.3892/ijmm.2015.2076.
52. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9:213-219. http://dx.doi.org/10.1038/nm820.
53. Ghisletti S, Huang W, Jepsen K, Benner C, Hardiman G, Rosenfeld MG, Glass CK. 2009. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and antiinflammatory signaling pathways. Genes Dev 23:681-693. http:// dx.doi.org/10.1101/gad.1773109.
54. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. 2003. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem 278:10443-10449. http:// dx.doi.org/10.1074/jbc.M213071200.
55. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY, Swiss Hepatitis C Cohort Study Group. 2011. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virusassociated steatosis. J Hepatol 55:529-535. http://dx.doi.org/10.1016/ j.jhep.2010.12.020.
56. Goossens N, Negro F. 2014. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 59:2403-2412. http://dx.doi.org/10.1002/hep.26905.
57. Rutledge H, Baran-Gale J, de Villena FP, Chesler EJ, Churchill GA, Sethupathy P, Kelada SNP. 2015. Identification of microRNAs associated with allergic airway disease using a genetically diverse mouse population. BMC Genomics 16:633. http://dx.doi.org/10.1186/s12864-015-1732-9.
58. Kurtz CL, Fannin EE, Toth CL, Pearson DS, Vickers KC, Sethupathy P. 2015. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep 5:12911. http://dx.doi.org/10.1038/srep12911.
59. Peck BCE, Weiser M, Lee SE, Gipson GR, Iyer VB, Sartor RB, Herfarth HH, Long MD, Hansen JJ, Isaacs KL, Trembath DG, Rahbar R, Sadiq TS, Furey TS, Sethupathy P, Sheikh SZ. 2015. MicroRNAs classify different disease behavior phenotypes of Crohn's disease and may have prognostic utility. Inflamm Bowel Dis 21:2178-2187. http://dx.doi.org/ 10.1097/MIB.0000000000000478.